Log In
Print this Print this

sovaprevir (formerly ACH-1625)

  Manage Alerts
Collapse Summary General Information
Company Achillion Pharmaceuticals Inc.
DescriptionSelective inhibitor of HCV NS3 protease
Molecular Target HCV NS3 protease
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 3 infection; Treat chronic HCV genotype 1 infection; Treat chronic HCV infection; Treat HCV genotype 1 infection
Regulatory Designation

U.S. - Fast Track (Treat chronic HCV infection)


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today